This federal Project Grant award, with ID R01DA059503, was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The $1,192,612 grant will fund a 5-year research project by The Miriam Hospital, a non-profit healthcare and research institution in Providence, RI, to integrate HIV prevention services into clinical care settings for people with opioid use disorder (OUD). The key objectives of this multidisciplinary research...
This Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) provides $569,743 to Yale University to conduct the "Y-SCORCH 2.0" research project. The goal is to further analyze transcriptomic and epigenetic data from the SCORCH consortium to identify potential treatment targets for the intersection of opioid use disorder (OUD) and HIV, which together affect over 20 million individuals globally. The key products and services...
This Project Grant award of $1,422,136 from the National Institutes of Health (CFDA 93.310 Trans-NIH Research Support) to Yale University aims to develop and evaluate novel methods to predict, detect, and diagnose outbreaks of HIV and other infectious diseases among people who use drugs. The key products and services to be delivered under this 5-year grant include: Developing modeling and pattern-recognition frameworks to predict jurisdictions at high risk of incipient infectious disease...
This Project Grant award of $688,271, provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports a research project at Yale University to examine spatial and temporal variability in a state's illicit drug market. The key activities under this award include: 1) Expanding street-based testing of drug samples from individuals who use drugs, 2) Developing a wastewater sampling and testing system to determine community-level drug...
This federal Project Grant award of $435,313 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to develop a cost-based epidemiological planning tool to guide public health response to the combined HIV, hepatitis C (HCV), and opioid use disorder (OUD) epidemics. Specifically, the project will: 1) Create an interactive, web-based dashboard to assist policymakers in planning an effective response and provide improved estimates...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $722,876 to New York University School of Medicine to conduct a study characterizing complex opioid use disorder (OUD) care trajectories and outcomes following acute service utilization. The study aims to: 1) characterize real-world trajectories of OUD treatment in the year following hospital encounters among treatment-naive individuals and...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), will provide $181,974 over 5 years to The Johns Hopkins University to conduct implementation science research optimizing HIV prevention and harm reduction services for men who have sex with men engaged in transactional sex in Baltimore, Maryland. The award will fund training and mentored research for the principal investigator, Dr. Atkins, to...
This $196,350 Project Grant was awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to Yale University. The grant will fund a project titled "HIV COMPLEX CAUSAL MODELING: GUT MICROBIOME, DRUG USE, AND IMMUNE RESPONSES" from August 1, 2024 to July 31, 2026. The project aims to elucidate the causal relationship between drug use disorders, HIV acquisition, gut microbiome, and immune responses using Mendelian randomization...
This federal Project Grant award of $683,583 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will support research to estimate the potential impacts of four alternative methadone treatment (MT) policy scenarios in New York State. The project will use an agent-based computer simulation model to analyze how changes to MT access points, such as through OTPs, mobile units, prescribers, and pharmacies, could influence methadone...
This federal Project Grant award of $157,684, provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), will fund a study to understand inequities in harm reduction services (HRS) provided to persons with opioid use disorder in hospital settings. The study will use natural language processing (NLP) and electronic health record (EHR) data to characterize providers' recommendations of psychosocial/environmental and...
This Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) provides $322,302 to Yale University to support research and training aimed at implementing medications for opioid use disorder (OUD) as an HIV prevention strategy in probation settings in Eastern Europe.
The key products and services to be delivered include: 1) Formal coursework, seminars, and interdisciplinary mentorship to expand the sociological research skills of the principal investigator, Dr. Azbel, in areas like ethnography, implementation science, and mixed methods; 2) Two research projects that use the EPIS framework to understand barriers and facilitators to implementing a screening-engagement-treatment (SET) strategy for scaling up opioid agonist therapy (OAT) in probation settings in Georgia and Moldova; and 3) Certification of Dr. Azbel as a NIATx coach to provide implementation support to probation change teams in Kyrgyzstan. The research aims to refine strategies that align probation officers' public safety focus with public health goals of reducing HIV transmission through facilitating OAT access for probation clients.